Scancell (LON:SCLP) Stock Price Down 3.2% - Should You Sell?

Key Points

• Scancell Holdings plc's stock price declined by 3.2%, trading at GBX 9.69 ($0.13) after hitting a low of GBX 9.60 during mid-day trading.
• Insider Martin Diggle purchased 4,400,000 shares at an average price of GBX 10, indicating insider confidence despite the recent stock price drop.
• Scancell is a clinical stage immunotherapy biotech company focused on developing innovative cancer treatments to address significant unmet medical needs.

Shares of Scancell Holdings plc (LON:SCLP - Get Free Report) were down 3.2% during trading on Tuesday . The company traded as low as GBX 9.60 ($0.13) and last traded at GBX 9.69 ($0.13). Approximately 1,336,894 shares were traded during trading, an increase of 44% from the average daily volume of 925,977 shares. The stock had previously closed at GBX 10 ($0.13).

Scancell Stock Performance

The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01. The stock's 50-day simple moving average is GBX 10.15 and its 200 day simple moving average is GBX 9.63. The stock has a market capitalization of £91.12 million, a P/E ratio of -422.12 and a beta of 0.35.

Insider Activity

In other Scancell news, insider Martin Diggle bought 102,236 shares of Scancell stock in a transaction dated Thursday, August 7th. The stock was bought at an average price of GBX 11 per share, with a total value of £11,245.96. Insiders own 15.15% of the company's stock.

Scancell Company Profile

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.